These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29763632)

  • 1. Lack of value of juvenile animal toxicity studies for supporting the safety of pediatric oncology phase I trials.
    Visalli T; Bower N; Kokate T; Andrews PA
    Regul Toxicol Pharmacol; 2018 Jul; 96():167-177. PubMed ID: 29763632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of juvenile animal studies to support oncology medicine development in children.
    Duarte DM
    Reprod Toxicol; 2015 Aug; 56():97-104. PubMed ID: 25998230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
    Le Tourneau C; Stathis A; Vidal L; Moore MJ; Siu LL
    J Clin Oncol; 2010 Mar; 28(8):1401-7. PubMed ID: 20124167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric phase I trials in oncology: an analysis of study conduct efficiency.
    Lee DP; Skolnik JM; Adamson PC
    J Clin Oncol; 2005 Nov; 23(33):8431-41. PubMed ID: 16293874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans.
    Duarte DM; Silva-Lima B
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):353-8. PubMed ID: 21594973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
    Colin P; Micallef S; Delattre M; Mancini P; Parent E
    Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovations for phase I dose-finding designs in pediatric oncology clinical trials.
    Doussau A; Geoerger B; Jiménez I; Paoletti X
    Contemp Clin Trials; 2016 Mar; 47():217-27. PubMed ID: 26825023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
    Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.
    Doussau A; Thiébaut R; Paoletti X
    Stat Med; 2013 Dec; 32(30):5430-47. PubMed ID: 24018535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New adaptive method for phase I trials in oncology.
    Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
    Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conduct of phase I trials in children with cancer.
    Smith M; Bernstein M; Bleyer WA; Borsi JD; Ho P; Lewis IJ; Pearson A; Pein F; Pratt C; Reaman G; Riccardi R; Seibel N; Trueworthy R; Ungerleider R; Vassal G; Vietti T
    J Clin Oncol; 1998 Mar; 16(3):966-78. PubMed ID: 9508179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.
    Le Tourneau C; Razak AR; Gan HK; Pop S; Diéras V; Tresca P; Paoletti X
    Eur J Cancer; 2011 Jul; 47(10):1468-75. PubMed ID: 21482105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
    Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
    Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.
    van Brummelen EM; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
    J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):235-42. PubMed ID: 26960536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.
    Dorris K; Liu C; Li D; Hummel TR; Wang X; Perentesis J; Kim MO; Fouladi M
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27654490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Juvenile Animal Studies for Pediatric CNS-Targeted Compounds: A Regulatory Perspective.
    van der Laan JW; van Malderen K; de Jager N; Duarte D; Egger GF; Lavergne F; Roque CG; Vieira I; Wiesner L; Carleer J
    Int J Toxicol; 2019; 38(6):456-475. PubMed ID: 31662008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity.
    Seymour L; Eisenhauer E
    Cancer Chemother Pharmacol; 2001; 47(1):2-10. PubMed ID: 11221956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.